2000%!!! - 500 Beiträge pro Seite

[jmiconors]

laut neuster empfehlung von prudential kursziel 54$ von derzeit 2,x...

position zulegen oder auf amis warten...

gruss jmi

[BarnyXXL]

IST KEINE NEUESTE EMPFEHLUNG !!!!

DU MUSST DIE MELDUNG RICHTIG DURCHLESEN !!!

Die Analysten von Prudential Securities bewerten in ihrer Analyse vom Dienstag, 9. März 2004 die Aktie von Targeted Genetics Corporation nach wie vor mit dem Rating " Overweight" . Das Kursziel für die Aktie liegt momentan bei 54 $.

© finanzen.net



Gruß Barny

[jmiconors]

sorry aber wenn in einer neuesten analyse eine alte bewertung vom 20fachen des aktuellen kursniveaus bestätigt wird, halte ich das durch aus für eine neue(ste) empfehlung...(bitte nicht haare spalten!)

verrückt wie die amis sind passiert garnix oder bald zweistellig.

gruss jmi

[jmiconors]

halte da eher deinen vergleich von prudential mit frick und co. für zweifelhafter...

www.prudential.com

[789456123]

Sicher steigen die auf 54$, aber noch in diesem Jahrtausend ??

[BarnyXXL]

@ 4:

Es war kein Vergleich, sondern eine Frage !

789456123 hat schon recht: Wann werden 54$ erreicht ?

Gruß Barny

[jmiconors]

glaube ja auch nicht an 54$, aber vielleicht gehts ja mal richtung zweistellig, wär doch fein

[BarnyXXL]

@ 7:

Für den, der investiert ist, schon.

Ich halte mich da raus, solange ich nicht mehr über die Firma weiss!

Gruß Barny

[ds99]

SEATTLE, March 18 /PRNewswire-FirstCall/ -- Todd E. Simpson, chief financial officer of Targeted Genetics Corporation , will speak at Invest Northwest, a life sciences and CEO investor conference on Tuesday, March 23, 2004. Mr. Simpson will provide a corporate overview, along with highlights from the Company``s AIDS vaccine, cystic fibrosis and arthritis programs. Presentation details are as follows:

What: Invest Northwest 2004 Conference Where: Seattle, WA Bell Harbor Conference Center When: Tuesday, March 23, 2004 11:00 a.m. PST

An archived version of Mr. Simpson``s slide presentation will be available at http://www.targetedgenetics.com/.

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at http://www.targetedgenetics.com/.

NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our annual report on Form 10-K for the year ended December 31, 2003. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Targeted Genetics Corporation

© PR Newswire


Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

TARGETED GENETICShttp://www.finanznachrichten.de/nachrichten-aktien/targeted-…

[bl21]

Habe ich das richtig Verstanden das das Kursziel für Target von 54 dollar bis ende des Jahres 2004 gilt?Dann müßte das eine oder andere (Krebs)Medikament schon in den Startlöchern stehen,oder was mein ihr?

[jmiconors]

ja, der aidsimpfstoff ist in der ersten klinischen testphase (war ja viel in der presse)--wenn da ein positiver(?) zwischenbericht zu erwarten ist, wäre das schon klasse (und könnte dann locker zweistelligen kurs bedeuten), zumal ich mich jetzt ein bisschen eingekauft habe....

[bl21]

Und wann soll,wenn alles glatt geht,dieser Impstoff auf den markt kommen?2006 oder später?

[jmiconors]

hhmm, sieht jetzt nicht schlecht aus...mal schaun

[jmiconors]

hhmm langfristiger aufwärts ist in takt

[abauer1050]

TARGETED GENETICS TO PRESENT AT EUREGENETHY THIRD ANNUAL INTERNATIONAL CONFERENCE, 4/13/04
Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics Corporation, will speak at two events during the Euregenethy Third Annual International Conference on Thursday, April 15, 2004. Dr. Carter is an expert in the field of gene-based therapies, and has over 20 years of experience in the development of adeno-associated viral (AAV) vectors for commercial applications. Targeted Genetics is utilizing its AAV vector technology in three product development programs: tgAAVCF for the treatment of cystic fibrosis (CF), the most advanced CF gene therapy clinical program to date; tgAAC09 for the prevention of AIDS; and tgAAC94 for the treatment of rheumatoid arthritis (RA). Dr. Carter will give a presentation focused on the Company’s RA clinical program, and the potential benefits of targeted gene delivery directly to affected joints of patients suffering from this disease. Dr. Carter also will participate in a press conference focused on clinical progress in the field of gene delivery.

TARGETED GENETICS ANNOUNCES CONCLUSION OF JOINT VENTURE RELATIONSHIP WITH ELAN, 4/6/04
Targeted Genetics Corporation today announced an agreement with Elan Corporation, plc that formally concludes the collaboration between the companies through the joint venture, Emerald Gene Systems, Ltd. (Emerald). Operating activities within the joint venture were completed in August 2002. This agreement represents the formal termination of the joint venture and various related matters. In connection with execution of the Termination Agreement, Elan has converted all the shares of Targeted Genetics Series B preferred stock into 4.33 million shares of Targeted Genetics common stock.



http://www.targen.com/investor/press-releases.php/y=2004

[bl21]

Waren die 54 dollar eigentlich für 2004 oder 2006 als Kursziel angesezt,oder wie war das nochmal?

[kopfeck]

Hallo

Gestern über 7% + in USA,und das nur weil am Mittwoch
die Zahlen kommen ???

Dann werden die wohl gut sein oder ??

Bin am überlegen ob ich eine kleine Position aufbaue.

Gibts Aktuelle Meinungen von Euch bereits Investierten.
Ist ja sehr ruhig im Thread.


bye Kopfeck

[CaptainProton]

@ #11

Kannst Du bitte mal posten wo etwas über den AIDS (eigentlich ja HIV) Impfstoff zu lesen war?

Ich habe nichts konkretes gefunden.

Vielen Dank.

[abauer1050]

TARGETED GENETICS REPORTS FIRST QUARTER 2004 FINANCIAL RESULTS, 4/28/04

Seattle, WA – April 28, 2004 – Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter of 2004. As previously announced, the Company will hold a conference call with analysts at 10:30 AM EDT today. The call will be broadcast live over the Internet and can be accessed, along with replay information, at www.targetedgenetics.com.

For the first quarter of 2004, the Company reported a net loss of $4.9 million, or $0.07 per common share, compared to $830,000, or $0.02 per common share for the first quarter of 2003. Revenue for the first quarter of 2004 was $1.3 million compared to $5.6 million for the first quarter of 2003. Revenue in 2004 consists primarily of revenue earned under the Company`s AIDS vaccine collaboration with the International AIDS Vaccine Initiative (IAVI). Revenue for the three months ended March 31, 2003 includes $4.7 million of revenue related to the termination of the Company`s former collaboration with Wyeth, and revenues earned under the Company`s collaboration with Biogen, which ended in September 2003.

"Targeted Genetics completed another successful quarter, with significant progress made in each of its three product development programs," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. “We have now accrued the patients required to conduct an interim analysis in our Phase II clinical trial of tgAAVCF in patients with cystic fibrosis. This analysis, conducted by an independent data safety monitoring committee, will provide us with the assessment necessary to continue with our trial. During the quarter, we also announced the initiation of our Phase I rheumatoid arthritis clinical trial. This study will be our first opportunity to test direct injection of tgAAC94 into the joints of those suffering from this debilitating disease. We also continue to accrue patients into our AIDS vaccine clinical trial."

Operating expenses were $6.2 million for the first quarter of 2004 and the first quarter of 2003. Research and development expenses decreased to $4.2 million for the three months ended March 31, 2004 from $4.5 million for the same period of 2003. General and administrative expenses for the first quarter of 2004 were $1.8 million, compared to $1.3 million for the same period in 2003.

In March, the Company formally concluded its joint venture with Elan Corporation plc (NYSE: ELN) called Emerald Gene Systems (Emerald). While operationally the joint venture had been inactive since 2002, a termination agreement was executed with Elan, addressing several topics related to termination of the joint venture. As a result, the Company received all intellectual property associated with the joint venture, reduced the number of shares issued upon conversion of its Series B Preferred Stock to 4.33 million shares, and stopped the accrual of further dividends on the preferred stock. Under the termination agreement, Elan is permitted to transfer its holdings of the Company’s common stock over time on a volume-restricted basis.

First quarter highlights include:

∑ Completion of $25.5 million financing, increasing our cash and cash equivalents to $41.1 million at the end of the first quarter;
∑ Extension of AIDS vaccine collaboration through 2006, providing up to $10.7 million in funding for 2004;
∑ Initiation of Phase I rheumatoid arthritis clinical trial in the U.S. and Canada;
∑ Publication of Phase II cystic fibrosis results in Chest, the official publication of the American College of Chest Physicians; and
∑ Conclusion of Emerald Gene Systems joint venture, with intellectual property rights obtained by Targeted Genetics.

Targeted Genetics develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company visit its website at www.targetedgenetics.com.

NOTE: This release contains forward-looking statements regarding our projected financial resources, intellectual property, clinical trials and regulatory filings and anticipated data from our clinical and preclinical programs. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including failure of our partners to provide funding, our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain or maintain regulatory approvals, our failure to maintain or protect our intellectual property and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Annual Report on Form 10-K for the year ended December 31, 2003. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectation.

Please click here for selected financial information

http://www.targen.com/investor/pr-detail.php/id=171

[abauer1050]

TARGETED GENETICS TO PRESENT AT THE 7TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE THERAPY - Presentations Demonstrate Broad Potential of Company’s AAV Technology -, 5/26/04

Seattle, WA — May 26, 2004 — Targeted Genetics Corporation’s (NASDAQ: TGEN) technology assets will be highlighted in 12 presentations during the 7th Annual Meeting of the American Society of Gene Therapy. The meeting will take place June 2 – June 6 in Minneapolis, MN. Presentations will focus on the Company’s core product development programs and the utility of adeno-associated virus (AAV) vector delivery technology. Targeted Genetics currently has three AAV-based product candidates in clinical development, including an AIDS vaccine and treatments for cystic fibrosis and rheumatoid arthritis.

Presentations are as follows:

Rheumatoid Arthritis
Abstract #99
Long-Term Expression of Soluble TNFR:Fc Protein Following Multiple Administrations of AAV-TNFR:Fc Vector Pseudotyped with Capsids of Alternate Serotypes. Thursday, June 3. Poster presentation.

Workshop #224
Musculo-Skeletal: Designing and Planning Clinical Trials for Musculo-Skeletal Diseases. AAV-TNFR:Fc Gene Therapy for Inflammatory Joint Diseases. Thursday, June 3. Oral presentation.

Abstract #880
Suppression of Inflammation in a Rat Model of Arthritis Following Intramuscular Administration of AAV-TNFR:Fc Vector Pseudotyped with AAV Type 1 Capsid. Saturday, June 5. Poster presentation.

Abstract #881
Preclinical Safety Assessment of Intra-Articular Administration of rAAV-humanTNFR:Fc in Rats in Support of a Phase I Arthritis Trial. Saturday, June 5. Poster presentation.

Cystic Fibrosis
Abstract #489
Comparison of AAV2 and AAV2/5 CFTR Vectors in the Lungs of Cynomolgus Macaques. Friday, June 4. Poster presentation.

Abstract #756
Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-mediated Transduction from the Apical Surface of Human Airway Epithelia. Saturday, June 5. Poster presentation.

Abstract #760
Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmico-Gene Therapy of the Cystic Fibrosis Airway. Saturday, June 5. Poster presentation.

AIDS Vaccine
Scientific Symposium #401
Gene-Based Vaccines: Clinical Applications of Gene-Based Vaccines and Immunotherapeutics (Biodefense, Vaccines, Cancer). Saturday, June 5. Oral presentation.

Core Technology: Adeno-Associated Virus (AAV) Vectors
Abstract #12
A New Class of Hybrid Adeno-Associated Viral Vectors with Non-Homologous ITRs Improves Directional Recombination and Dual-Vector Reconstitution of Large Transgenes. Thursday, June 3. Oral presentation.

Abstract #346
Characterization of Adeno-Associated Virus Sequences in Human Tissues. Friday, June 4. Oral presentation.

Abstract #744
Genetic Structure of Adeno-Associated Virus DNA in Human Tissues. Saturday, June 5. Poster presentation.

Abstract #754
Intracellular Trafficking Patterns of rAAV2 Demonstrate Significant Cell-Type Specificity. Saturday, June 5. Poster presentation.

For more information about the 7th Annual Meeting of the American Society of Gene Therapy, please refer to www.asgt.org.

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our regulatory filings, research programs, clinical trials, product development and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our ability to recruit and enroll suitable trial participants, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.


http://www.targen.com/investor/pr-detail.php/id=173

[BarnyXXL]

TGEN scheint ja langsam wieder anzuspringen,

SK Nasdaq 1,89 USD !

[abauer1050]

TARGETED GENETICS PRESENTS PRECLINICAL DATA FROM RHEUMATOID ARTHRITIS PROGRAM AT THE 7TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE THERAPY - Results Support Efficacy, Safety and Broad Utility of AAV Technology -, 6/3/04

Minneapolis, MN and Seattle, WA—June 3, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) will present results of preclinical studies supporting its rheumatoid arthritis program today in two sessions during the 7th Annual Meeting of the American Society of Gene Therapy in Minneapolis, MN. Targeted Genetics is currently conducting a Phase I clinical trial in patients with rheumatoid arthritis. The product candidate, tgAAC94, utilizes the Company’s recombinant adeno-associated viral (rAAV) vector technology platform to deliver the DNA sequence encoding a potent inhibitor of tumor necrosis factor (TNF-alpha), known as TNFR:Fc, directly into affected joints of patients suffering from rheumatoid arthritis. Data presented today will highlight data from studies evaluating multiple routes of delivery of tgAAC94.

Haim Burstein, Ph.D., senior director of product discovery at Targeted Genetics, will present in two different sessions throughout the day. The first presentation is during the workshop session #WS224 titled, “Musculo-Skeletal: Designing and Planning Clinical Trials for Musculo-Skeletal Diseases.” Dr. Burstein’s presentation will include an overview of Targeted Genetics’ product candidate, tgAAC94, encouraging preclinical results, and current clinical program status. Preclinical results to date testing tgAAC94 have demonstrated suppression of arthritis, as measured by arthritis index scores that include a decrease in cartilage and bone destruction and inflammatory cell infiltration. No safety issues related to the product candidate have been observed in preclinical studies.

Dr. Burstein also will present Abstract #99, titled “Long-Term Expression of Soluble TNFR:Fc Protein Following Multiple Administrations of AAV-TNFR:Fc Vector Pseudotyped with Capsids of Alternate Serotypes” in a poster session during the afternoon.
In this study, different routes of administration, as well as alternate capsid serotypes of AAV vectors, were tested. Both intramuscular and intravenous administration resulted in sustained, high levels of secreted soluble TNFR:Fc protein in the systemic circulation for over a year. Following pulmonary delivery of tgAAV-ratTNFR:Fc vector, soluble TNFR:Fc protein was observed in serum. Maximum expression of TNFR:Fc protein in the circulation was achieved within six weeks after administration and gradually declined over a period of eight months. Repeat administration via pulmonary delivery resulted in renewed expression. Pulmonary administration elicited serum anti-AAV capsid neutralizing antibody responses, but these did not prevent lung transduction and efficient secretion of TNFR:Fc protein to the circulation following repeat administration.

“Data presented today demonstrate the diverse assets of Targeted Genetics’ AAV technology, providing both a localized and systemic delivery approach to treatment of rheumatoid arthritis,” said Dr. Burstein. “Use of AAV to deliver the DNA sequence encoding TNFR:Fc directly into affected joints has resulted in suppression of arthritis in animal models as evidenced by decreased articular index score, inflammatory cell infiltration, pannus formation and cartilage and bone destruction. Presentation of additional preclinical data today suggest that various routes of administration used to deliver AAV vectors, along with different capsid serotypes of AAV, yield long-term expression of TNFR:Fc protein. We believe these data continue to support the broad potential of Targeted Genetics’ AAV gene delivery technology to treat systemic TNF-a mediated autoimmune diseases such as rheumatoid arthritis.”

Targeted Genetics’ Current Phase I Clinical Trial
Targeted Genetics’ Phase I clinical trial is a multi-center, randomized, double-blind, placebo-controlled, dose escalation study designed to assess safety of intra-articular delivery of tgAAC94. Other secondary parameters assessed are the ability of intra-articular administration of tgAAC94 to reduce pain and swelling in the injected joint and overall disease activity. The amount of local and circulating TNFR:Fc protein also will be measured. The trial is being conducted in the U.S. and Canada, and will ultimately enroll up to 32 patients. Participants will receive a single injection of tgAAC94 or placebo directly into an affected joint and will be followed for 24 weeks following injection. This clinical trial is based on prior preclinical data testing intraarticular administration of the product candidate directly into affected joints. Results demonstrated localized expression of the protein in targeted joints without significantly elevated levels of circulating TNFR:Fc protein.

About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our regulatory filings, research programs, clinical trials, product development and potential related to tgAAC94 and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our preclinical results with animals are not necessarily indicative of results that will be obtained in humans, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property related to tgAAC94, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

[abauer1050]

TARGETED GENETICS SIGNS EXCLUSIVE LICENSE AGREEMENT WITH NATIONAL INSTITUTES OF HEALTH - Agreement Expands AAV Product Opportunities -, 6/4/04

Seattle, WA — June 4, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) today announced it has signed an exclusive worldwide license with the National Institutes of Health (NIH) for patents that cover ITR (inverted terminal repeat) sequences as a promoter when utilizing adeno-associated viral (AAV) vectors for any product indication. Financial terms of the agreement were not disclosed.

This exclusive worldwide license covers a family of U.S. and foreign patents and patent applications related to Patent #5,587,308 entitled, “Modified Adeno-Associated Virus Vector Capable of Expression from a Novel Promoter.” Prior to today’s announcement, Targeted Genetics had exclusive rights to the same technology for use in the field of cystic fibrosis. This agreement expands rights under this family of patents to all AAV-based product indications. This technology was invented and patented by Barrie Carter, Terence Flotte, Sandra Afione and Rikki Solow. Dr. Carter currently serves as chief scientific officer of Targeted Genetics and invented and patented this technology during his tenure at the NIH.

“Targeted Genetics continues to maintain its leadership position in the development of AAV-based products to treat or prevent disease. The Company now has three AAV-based clinical programs currently in development,” said H. Stewart Parker, president and chief executive officer of Targeted Genetics. “There are certain disease states in which the therapeutic replacement gene plus an additional promoter element is too large to fit in a single AAV vector. The use of ITR as the promoter, along with these genes, allows for expression of the therapeutic gene while still providing opportunity for it to be packaged into a single AAV vector. Through this new license agreement with NIH, we are able to significantly broaden product development opportunities through use of our AAV technology.”

AAV vectors are utilized in Targeted Genetics’ product development programs to deliver a gene of interest into targeted cells to treat or prevent disease. AAV vectors are comprised of an AAV capsid that contains a therapeutic gene of interest flanked on both ends by an AAV segment called an ITR. ITRs are necessary to package the therapeutic gene of interest into the AAV capsids. ITRs have also been demonstrated to function as promoters in product constructs for diseases such as cystic fibrosis, wherein the therapeutic gene is so large that traditional promoters linked to the therapeutic gene flanked by these ITRs cannot fit into the AAV capsid. In serving this dual function, ITRs as promoters may provide new opportunities for potential treatment of a wide variety of diseases.

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our research programs, clinical trials, product development and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our ability to recruit and enroll suitable trial participants, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

[bl21]

Weiß irgend jemand wann die nächsten Zahlen kommen?Und hat jemand von dem Aids-impfstoff news gehört?

[abauer1050]

Corporate CommunicationsTARGETED GENETICS’ AAV TECHNOLOGY HIGHLIGHTED IN VACCINE SYMPOSIUM AT THE 7TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE THERAPY, 6/7/04

Minneapolis, MN and Seattle, WA—June 7, 2004 —Targeted Genetics Corporation (NASDAQ: TGEN) announced that its rAAV (recombinant adeno-associated viral) vector technology was highlighted for its potential utility in the prevention of AIDS at the 7th Annual Meeting of the American Society of Gene Therapy. Philip R. Johnson, MD, president of the Columbus Children’s Research Institute (CCRI) presented this topic during a scientific symposium titled, “Gene-Based Vaccines: Clinical Applications of Gene-Based Vaccines and Immunotherapeutics (Biodefense, Vaccines, Cancer).” Dr. Johnson discussed the unique attributes of AAV, and its potential to play a role in preventing disease. He focused on Targeted Genetics’ ongoing program utilizing rAAV technology as a vaccine candidate to prevent AIDS.

CCRI is one of the collaborative partners participating in Targeted Genetics’ rAAV-based AIDS vaccine clinical program. In this clinical program, rAAV vectors are used to deliver select genes from the HIV genome into healthy volunteers in an attempt to elicit immune system responses to prevent AIDS. The current product candidate now in a Phase I clinical trial, tgAAC09, is designed to elicit two different types of immune responses, an antibody response and a cell-mediated response, after a single-shot administration of the product candidate. The International AIDS Vaccine Initiative also is a partner in this collaborative effort.

“Utilization of rAAV-based gene delivery offers significant strategic advantages, making this technology uniquely qualified to play a role in disease prevention,” said Dr. Johnson. “AAV is a small, stable, naturally occurring virus with high level expression capabilities. Preclinical results from our rAAV-based AIDS vaccine program were quite encouraging, and we have now moved our program into clinical development, providing us with the first opportunity to observe results of our rAAV-based vaccine candidate in humans. If proven effective, this may provide the basis for potential use of rAAV in other vaccine settings.”

During Dr. Johnson’s presentation, he reviewed various preclinical results compiled in support of a clinical program testing an rAAV-based vaccine to prevent AIDS. Highlighted preclinical results included:

∑ No dose-related or clinically significant safety issues;
∑ Vaccine did not integrate into host chromosome;
∑ Robust and sustained dose-dependent antibody and antigen-specific T cell responses; and
∑ Vaccinated animals were protected from disease with statistically significant reduced viral load at peak and set-point.

In December 2003, the collaboration initiated a Phase I clinical trial of tgAAC09 as a single-shot AIDS vaccine candidate. The Phase I, dose-escalation clinical trial is a double-blind, placebo-controlled study that will enroll up to 50 volunteers, both men and women, who are uninfected with HIV and in good general health. Each volunteer receives a single intramuscular injection into the upper arm. Following vaccination, study participants will be monitored for safety and evaluated to see if tgAAC09 can elicit an immune response.

About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our research programs, clinical trials, product development and potential related to tgAAC09 and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our preclinical results with animals are not necessarily indicative of results that will be obtained in humans, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property related to tgAA09, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

[abauer1050]

ARGETED GENETICS’ PRECLINICAL RESULTS DEMONSTRATE COMPLETE SUPPRESSION OF RHEUMATOID ARTHRITIS DURING STUDY, 6/7/04

Minneapolis, MN and Seattle, WA—June 7, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) presented preclinical results on Saturday supporting utility of its product candidate to treat rheumatoid arthritis. Studies to evaluate the long-term effect of TNFR:Fc expression on disease resulted in a complete suppression of rheumatoid arthritis over a three-month observation period in animal models. These data were presented on Saturday at the 7th Annual American Society of Gene Therapy Meeting in Minneapolis, MN. Targeted Genetics is currently conducting a Phase I clinical trial in patients with rheumatoid arthritis. The product candidate, tgAAC94, utilizes the Company’s recombinant adeno-associated viral (rAAV) vector technology platform to deliver the DNA sequence encoding a potent inhibitor of tumor necrosis factor (TNF-alpha), known as TNFR:Fc, directly into affected joints of patients suffering from rheumatoid arthritis.

Abstract #880, titled “Suppression of Inflammation in a Rat Model of Arthritis Following Intramuscular Administration of AAV-TNFR:Fc Vector Pseudotyped with AAV Type 1 Capsid,” was presented in a poster session on Saturday afternoon by Haim Burstein, Ph.D., senior director of product discovery at Targeted Genetics. In this study, rats with experimental arthritis were injected intramuscularly with AAV-TNFR:Fc vectors with AAV1 serotype capsids. The data demonstrated efficient, long-term and sustained secretion of soluble TNFR:Fc protein to the systemic circulation. More importantly, when recurring flares of inflammation were introduced again into joints of these rats, disease was suppressed.

“Today’s presentations represent Targeted Genetics’ growing body of data supporting development of its product candidate to treat rheumatoid arthritis,” said Dr. Burstein. “We continue to demonstrate in preclinical studies, safety and efficacy of AAV-based treatment of inflammatory arthritis. In addition, we continue to observe positive preclinical results favoring use of our AAV technology to treat rheumatoid arthritis over sustained periods of time. The evidence of extensive suppression of disease in a preclinical setting suggests the potential utility of AAV vectors for long-term systemic delivery of secreted soluble TNFR:Fc protein.”

A concurrent poster (Abstract #881) also was presented on Saturday discussing Targeted Genetics’ rheumatoid arthritis program. The poster presentation, titled “Preclinical Safety Assessment of Intra-Articular Administration of rAAV-humanTNFR:Fc in Rats in Support of a Phase I Arthritis Trial,” discussed preclinical safety of our product candidate currently in a Phase I clinical trial. Lewis rats received either vehicle control, rAAV-ratTNFR:Fc, or one of three different doses of rAAV-humanTNFR:Fc via intra-articular injection. Clinical observations were performed on a daily and weekly basis, along with observations at sacrifice. The results demonstrate that the product candidate was well tolerated and gene expression was confirmed. The highest dose tested did not result in toxicity. These data, in addition to other safety and efficacy data, support clinical evaluation of tgAAC94 currently underway.

“As we advance our tgAAC94 product development program, Targeted Genetics continues to further understand the potential of our AAV technology and its role in the treatment of inflammatory diseases,” said H. Stewart Parker, president and chief executive officer of Targeted Genetics. “With several AAV-based product candidates currently in clinical development, we are leveraging AAV assets, such as long-term expression, safety and stability profile, and diverse product applicability, with the goal of product commercialization. As the first company to bring AAV-based products into the clinic, we continue to maintain our leadership role in AAV product development.”

About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our research programs, clinical trials, product development and potential related to tgAAC94 and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our preclinical results with animals are not necessarily indicative of results that will be obtained in humans, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property related to tgAAC94, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

[abauer1050]

TARGETED GENETICS TO PRESENT IN GENE THERAPY FORUM AT BIO 2004, 6/8/04

San Francisco, CA and Seattle, WA — June 8, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) will present in a scientific session today titled, “The State of Gene Therapy Today” at BIO 2004 in San Francisco, CA. Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics, will serve as the Chair of this session, and also will present the latest developments in Targeted Genetics’ product development programs.

The purpose of the session is to present a global overview of the state of gene therapy, discuss advancements made in technology, manufacturing techniques, and specific examples of the latest developments in the field.

What: Scientific Session: The State of Gene Therapy Today
When: Tuesday, June 8, 2004
9:30 AM – 10:45 AM PDT
Where: BIO 2004
San Francisco, CA
Moscone Convention Center
2016 West

“Today’s panel brings together representatives from leading companies making progress in the field of gene therapy product development,” said Dr. Carter. “These organizations continue to build a growing body of data, suggesting strong safety and encouraging clinical results that bring us closer to the goal of product commercialization.”


About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at www.targetedgenetics.com.

NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical or clinical programs, our failure to obtain or maintain regulatory approvals, our failure to maintain or protect our intellectual property and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

[abauer1050]

http://www.targen.com/home.php

Die Quelle zu den obigen 3 Postings

[bl21]

Was ist denn jezt nun mit diesem Schrott los ,hat der Absturz nun definitiv begonnen oder was ?

[abauer1050]

RESULTS FROM INTERIM ANALYSIS SUPPORT CONTINUATION OF TARGETED GENETICS’ PHASE IIB CYSTIC FIBROSIS CLINICAL TRIAL - Clinical Trial Remains on Track for Completion of Patient Dosing by End of 2004 -, 6/23/04

Seattle, WA—June 23, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) today announced that an independent data monitoring committee (DMC) met for its scheduled interim analysis of a Phase IIb clinical trial of the Company’s product candidate, tgAAVCF, to treat patients with cystic fibrosis (CF). Based upon its review, the DMC recommended continuation of the study as planned. The DMC provided its recommendation based upon an analysis of whether or not there was a chance that, upon full patient enrollment, the study could show a statistically significant positive impact on lung function measurements in patients treated with tgAAVCF compared to placebo.

“Targeted Genetics’ ongoing Phase IIb clinical trial has advanced further than any other CF gene therapy program to date, and we are pleased to continue this study based on the DMC’s recommendation,” said H. Stewart Parker, president and chief executive officer of Targeted Genetics. “This recommendation allows us to continue to generate clinical results and assess the ability of this product candidate to improve lung function in patients with CF. There remains a significant unmet need in the CF patient community for treatments that address the underlying cause of this chronic disease. We are optimistic about this trial and hope it will lead to a true advance in the treatment of CF.”

This Phase IIb, double-blind, randomized, placebo-controlled study is partially funded by Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, and is being conducted through CFFT’s Therapeutics Development Network. The trial includes bi-monthly evaluation of lung function after repeat dosing of tgAAVCF. Researchers also are assessing the impact of tgAAVCF on inflammation and biologic markers over time when compared to placebo. The study continues to monitor the safety and tolerability profile of tgAAVCF. A total of 100 patients, 12 years of age and older, are being evaluated, 50 in the treatment group and 50 in the placebo group. Study participants receive two doses of 1x1013 DNAse resistant particles (DRP) of tgAAVCF or placebo, delivered via nebulizer at day 0 and day 30 of the study and are evaluated for efficacy every two weeks for a total of 90 days. Study participants are being monitored for safety for seven months.

The planned interim analysis was conducted after 53 patients were dosed with either the product candidate or placebo. The DMC did not raise any safety concerns and recommended continuation of the trial. In order to protect the integrity of the trial, the complete, unblinded results will not be made available to Targeted Genetics until the study is completed. The DMC is an independent group of experts that was established by CFFT to monitor the safety and efficacy data. The primary role of the DMC is to safeguard the interests of current and future patients in the trial and act in an advisory capacity to Targeted Genetics and the Cystic Fibrosis Foundation.

About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about Targeted Genetics visit its website at www.targetedgenetics.com.

This release contains forward-looking statements regarding our research programs, clinical trials, product development and potential related to tgAAVCF and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our research and our clinical trials, our preclinical results with animals are not necessarily indicative of results that will be obtained in humans, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property related to tgAAVCF, and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

###

http://www.targen.com/investor/pr-detail.php/id=181

[abauer1050]

und noch eins vom 17.06.2004


TARGETED GENETICS FILES SHELF REGISTRATION STATEMENT, 6/17/04

Seattle, WA — June 17, 2004 — Targeted Genetics Corporation (NASDAQ: TGEN) announced today that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission (SEC) for the sale of up to 16,300,000 shares of its common stock. Upon being declared effective by the SEC, the shelf registration will provide Targeted Genetics the flexibility to sell common stock in one or more offerings at its discretion. The actual amount of common stock to be issued, if any, will be determined at the time of any sale, if such sale occurs.

The shelf registration statement relating to the common stock has been filed with the SEC but has not yet become effective. The common stock may not be sold, nor may offers to buy the common stock be accepted prior to the time the shelf registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state. For copies of the preliminary prospectus, please contact Targeted Genetics, Investor Relations at [phone].

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at www.targetedgenetics.com.

NOTE: This release contains forward-looking statements regarding offerings of our common stock in the future, which are based on opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by these forward-looking statements. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of these forward-looking statements. Factors that could affect our actual results include, but are not limited to, market conditions that prevent us from commencing or completing an offering on acceptable terms, if at all, changes in our financing plan, changes in our business, as well as the other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" included in our latest periodic report filed with the Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to reflect new information, circumstances or events after the date of this release or to reflect the occurrence of unanticipated events.

###

[bl21]

Keine News keine Analystenkommentare-Existiert diese Company überhaupt noch?

[BarnyXXL]

27.07.2004 14:45: Update Targeted Genetics Corporation: Buy

Die Aktie des Unternehmens Targeted Genetics (Nachrichten) Corporation wurde in einer Kurzanalyse vom Dienstag, 27. Juli 2004 von den Analysten der Fulcrum von "Neutral" auf "Buy" heraufgestuft. Das Kursziel für die Aktie liegt momentan bei 50 $.

© finanzen.net

[bl21]

Das diese sogennanten Analysten angesichts dieses Kursverlaufs sich trauen so ein Kursziel zu nennen ist absolut nicht nachvollziebar,es sei denn sie wissen etwas was wir (anleger)nicht wissen;und was bitte schön sollte das woll sein?

[BarnyXXL]

#34:

Vermutlich haben diese Analysten schon die Auswirkungen einbezogen, die eventuell eintreten, wenn TGEN seine in der klinischen Phase befindlichen Produkte erfolgreich auf den Markt bringt.

Eine andere Erklärung habe ich nicht.

Übrigens gibt es schon von mehreren Analysten Kursziele von jenseits 40 USD.

Ich sehe es mal als Langfristinvestment. Mal sehen, wie es in 2-3 Jahren aussieht.

Gruß Barny

[abauer1050]

TARGETED GENETICS INVITES YOU TO JOIN ITS SECOND QUARTER 2004 EARNINGS CALL ON THE WEB, 7/26/04

Seattle, WA – July 26, 2004 – Targeted Genetics Corporation (Nasdaq: TGEN) invites you to listen to its investor and analyst conference call, which will be held in conjunction with the release of the Company’s Second Quarter 2004 financial results. The call will be broadcast live over the Internet on Thursday, July 29, 2004, at 10:30 AM EDT.

What: Targeted Genetics Corporation Second Quarter 2004 Financial Results

When: July 29, 2004, 10:30 AM EDT

Where: www.targetedgenetics.com

If you are unable to participate during the live webcast, the call will be archived for 30 days at www.targetedgenetics.com. The replay also will be available for 30 days by dialing 800-207-7077 (domestic) or 913-383-5767 (international) and using PIN #4074.

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about the Company, visit its website at www.targetedgenetics.com.

NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our quarterly report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.


###
http://www.targen.com/investor/pr-detail.php/id=183

[abauer1050]

Habe auch noch ins Deutsche übersetzen lassen.
Aber ohne Gewähr was das Programm da rausgebracht hat



Gerichtete Genetik lädt Sie ein, sich ihrem zweiten Quartal anzuschließen, wo 2004 Verdienst den Netz, 26.7.4, weiterruft

Seattle, WA - 26. Juli 2004 richtete Genetikcorporation (Nasdaq: TGEN) lädt Sie ein, ihrem Anleger- und Analytikerkonferenzgespräch zuzuhören, das in Verbindung mit der Freigabe von den zweiten Viertel2004 finanziellen Ergebnissen der Gesellschaft gehalten wird. Der Anruf wird sein Sendung, die um 10:30 a.m. EDT am Donnerstag, dem 29. Juli 2004, über dem Internet live ist.

Was: Richtete zweites Viertel 2004 Genetikcorporation finanzielle Ergebnisse

Wann: Juli29, 2004, 10:30 a.m. EDT

Wo: www.targetedgenetics.com

Wenn Sie außerstande sind, während des Livewebcasts teilzunehmen, wird der Anruf 30 Tage bei www.targetedgenetics.com archiviert. Das Wiederholungsspiel wird auch für 30 Tage verfügbar durch Wählen von 800-207-7077 (häuslich) oder 913-383-5767 (international) und Benutzen der Nadel #4074es sein.

Gerichtete Genetikcorporation entwickelt genbasierte Produkte für das Verhindern und das Behandeln von bekommenen und erhaltenen Krankheiten. Die Gesellschaft hat drei klinische Produktentwicklungsprogramme, wenn sie Mukoviszidose, AIDS-Prophylaxe und rheumatische Arthritis richtet. Die Gesellschaft hat auch eine viel versprechende Rohrleitung von auf Bluterkrankheit und Krebs gerichteten Produktkandidaten und eine breite Bühne von Genliefertechniken. Zwecks weiterer Informationen über die Gesellschaft besuchen Sie ihre Website bei www.targetedgenetics.com.

Hinweis: Diese Freigabe enthält vorausblickende Erklärungen bezüglich unserer Produktrohrleitung und unseren klinischen Prüfungen. Diese Erklärungen schließen gegenwärtige Erwartungen, Vorhersagen von zukünftigen Ereignissen und andere Erklärungen ein, die nicht historische Fakten sind. Unrichtig, dass Annahmen und bekannte und unbekannte Risiken und Ungewissheiten die Genauigkeit von vorausblickenden Erklärungen beeinflussen kann. Tatsächliche Ergebnisse konnten sich materiell von Erwartungen aus einer Anzahl von Gründen unterscheiden, einschließlich unseres Unterlassens, Fortschritt bei unseren klinischen Prüfungen, unser Unterlassen, positive Ergebnisse von unseren preclinical Programmen zu erhalten, unser Unterlassen, rechtliche Genehmigung zu erhalten, und die im Abschnitt beschriebenen anderen Risiken berechtigt zu machen, "zerlegt beeinflussen unser laufen resultiert, unser das Geschäft und unser Vorrat auszeichnen" auf unser Vierteljahresschrift berichten auf Form 10-Q für das Viertel endete März 31, 2004. Sie sollten nicht übermäßig von diesen vorausblickenden Erklärungen abhängen, die zutreffen, nur wie vom Datum dieser Freigabe. Wir übernehmen keine Pflicht, öffentlich von Revisionen zu diesen Erklärungen anzukündigen oder zu berichten, dass, wie neue Information verfügbar wird, das unsere Erwartungen wechseln kann.

[BarnyXXL]

29.07.2004 14:06:
Targeted Genetics Reports Second Quarter 2004 Financial Results

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Targeted Genetics (Nachrichten) today announced its financial results for the second quarter of 2004. As previously announced, the Company will hold a conference call with analysts at 10:30 AM EDT today. The call will be broadcast live over the Internet and can be accessed, along with replay information, at http://www.targetedgenetics.com/.

For the second quarter of 2004, the Company reported a net loss of $4.5 million, or $0.05 per share, compared to $6.9 million, or $0.13 per share for the second quarter of 2003. For the six months ended June 30, 2004, the Company reported a net loss of $9.3 million, or $0.12 per share, compared to $7.7 million, or $0.15 per share for the same period in 2003.

Revenue for the three months ended June 30, 2004 increased to $2.8 million compared to $2.1 million for the second quarter of 2003, and was $4.1 million for the six months ended June 30, 2004, compared to $7.7 million for the same period in 2003. 2004 revenue reflects research and development activities under Targeted Genetics`` AIDS vaccine collaboration with the International AIDS Vaccine Initiative (IAVI) and revenue from completing its contract manufacturing agreement with GenVec.

"Progress in our three clinical development programs continues to be a top priority for us, and we made significant progress during the quarter. The successful completion of an interim analysis for Targeted Genetics`` Phase IIb cystic fibrosis clinical trial was a key highlight for the Company," said H. Stewart Parker, president and chief executive officer of Targeted Genetics. "This analysis, conducted by an independent data monitoring committee, led to their recommendation that we continue the trial as planned. We remain on target to complete enrollment in both our cystic fibrosis and AIDS vaccine clinical trials in 2004, while continuing to enroll patients in our rheumatoid arthritis clinical trial, which began during the first quarter of 2004. Our cash position remains healthy, providing us with the necessary resources to support plans for the next stages of product development."

Operating expenses were $7.1 million for the second quarter of 2004, down from $8.7 million for the second quarter of 2003, and were $13.3 million for the six months ended June 30, 2004, down from $14.8 million for the same period in 2003. 2004 expenses reflect increased research and development expenses, primarily attributable to the Company``s AIDS vaccine and rheumatoid arthritis programs and higher general and administrative expenses, reflecting increases in patent issuances and regulatory compliance costs. 2003 expenses included restructuring charges of $2.9 million for the three months and $3.2 million for the six months ended June 30, 2003, compared to $.2 million and $.4 million for the same periods in 2004.

Second quarter highlights include: -- Successful interim analysis from the Company``s cystic fibrosis Phase IIb clinical trial; trial on track for completion by year-end; -- Targeted Genetics`` AAV technology highlighted in 12 presentations at the 7th Annual Meeting of the American Society of Gene Therapy; -- Presentation of positive preclinical data from the Company``s rheumatoid arthritis program at ASGT, demonstrating complete suppression of disease during study after intramuscular injection; -- Issuance of additional patent giving Targeted Genetics exclusive rights to AAV1, providing expanded potential for future product development and partnering opportunities; -- Announcement of merger agreement between CellExSys and Chromos Molecular Systems; and -- Issuance of an exclusive worldwide license agreement with the National Institutes of Health (NIH) for patents that cover ITR (inverted terminal repeat) sequences as a promoter for use with AAV in any product indication.

Targeted Genetics develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about the Company visit its website at http://www.targetedgenetics.com/.

NOTE: This release contains forward-looking statements regarding our projected financial resources, intellectual property, clinical trials and regulatory filings and anticipated data from our clinical and preclinical programs. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including failure of our partners to provide funding, our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain or maintain regulatory approvals, our failure to maintain or protect our intellectual property and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectation.

TARGETED GENETICS CORPORATION (in thousands, except per share information) (unaudited) Three months ended Six months ended June 30, June 30, 2004 2003 2004 2003 Statement of Operations Information: Collaborative agreements with affiliates $2,761 $2,053 $4,081 $7,692 Operating expenses: Research & development 4,828 4,327 9,065 8,869 General & administrative 2,066 1,438 3,816 2,774 Restructure charges 221 2,899 416 3,180 Total operating expenses 7,115 8,664 13,297 14,823 Loss from operations (4,354) (6,611) (9,216) (7,131) Investment income 21 56 145 108 Interest expense (117) (360) (237) (722) Net loss $4,450 $(6,915) $(9,308) $(7,745) Net loss per common share $(0.05) $(0.13) $(0.12) $(0.15) Shares used in computation of net loss per common share 81,604 51,694 77,239 51,133 TARGETED GENETICS CORPORATION (in thousands) June 30, December 31, 2004 2003 (unaudited) Balance Sheet Information: Cash and cash equivalents $37,381 $21,057 Other current assets 554 575 Property and equipment, net 2,876 3,423 Other assets 32,462 32,617 Total assets $73,273 $57,672 Current liabilities $8,328 $6,709 Long-term obligations and other liabilities 16,231 16,734 Preferred stock and minority interest -- 750 Shareholders`` equity 48,714 33,479 Total liabilities and shareholders`` equity $73,273 $57,672

Targeted Genetics Corporation

[abauer1050]

R29.07.200414:06:
Gerichtete Genetik berichtet von zweiten Viertel2004 finanziellen Ergebnissen

Seattle, 29. Juli /PRNewswire-FirstCall/-gerichtete Genetik (Nachrichten) gab seine finanziellen Ergebnisse für das zweite Quartal von 2004 heute bekannt. Wie zuvor angekündigt, hält die Gesellschaft um 10:30 a.m. EDT heute ein Konferenzgespräch mit Analytikern. Der Anruf wird gesendet lebt über dem Internet und kann zugegriffen werden entlang mit Wiederholungsspiel Information bei http://www.targetedgenetics.com/.

Für das zweite Quartal von 2004 berichtete die Gesellschaft, dass ein Nettoverlust an $ 4,5 Millionen oder $ 0,05 pro Anteil für das zweite Quartal von 2003 mit $ 6,9 Millionen oder $ 0,13 pro Anteil verglichen war. Für die sechs 30. Juni 2004 beendeten Monate berichtete die Gesellschaft, dass ein Nettoverlust an $ 9,3 Millionen oder $ 0,12 pro Anteil mit $ 7,7 Millionen oder $ 0,15 pro Anteil für dieselbe Periode im Jahr 2003 verglichen war.

Einnahmen für die drei 30. auf $ 2,8 Millionen gesteigerter Juni 2004 beendeten Monate ließen sich mit $ 2,1 Millionen für das zweite Quartal von 2003 vergleichen und waren $ 4,1 Millionen die sechs Monate beendeter Juni 30, 2004, verglich zu $ 7,7 Millionen für die Gleichen Punkt in 2003. 2004 Einnahmen reflektieren Forschungs- und Entwicklungsaktivitäten unter gerichteter Genetik "hilft Impfstoffkollaboration mit der internationalen AIDS-Impfstoffinitiative (IAVI) und den internationalen Einnahmen davon, seine Vertragsherstellungsvereinbarung mit GenVec fertig zu stellen.

"Fortschritt bei unseren drei klinischen Entwicklungsprogrammen fährt fort, eine oberste Priorität für uns und wir zu sein, die bedeutsamer Fortschritt während des Viertels gemacht sind. Die erfolgreiche Fertigstellung einer Übergangsanalyse für gerichtete Genetik "durchführen IIb Mukoviszidose schrittweise klinische Probe war ein Schlüsselhöhepunkt für die Gesellschaft," sagte H. Stewart Parker, Präsidenten und Vorstandsvorsitzenden über gerichtete Genetik. "Diese Analyse, geführt von einem unabhängigen Datenüberwachungskomitee, führte zu ihrer Empfehlung, dass wir die Probe als geplant fortsetzen. Wir müssen erst noch auf Ziel Anmeldung für sowohl unsere Mukoviszidose als auch AIDS-Impfstoff beenden klinische Prüfungen in 2004, Weile, die fortfahren, Patienten für unsere rheumatische Arthritis einzuschreiben, klinische Probe, die während des ersten Quartals von 2004 begann. Unsere Barposition bleibt gesund, wenn sie uns die notwendigen Ressourcen liefert, Pläne für die nächsten Stufen der Produktentwicklung zu unterstützen."

Verwaltungskosten waren $ 7,1 Millionen für das zweite Quartal von 2004 von $ 8,7 Millionen für das zweite Quartal von 2003 herunter und waren $ 13,3 Millionen die sechs 30. Juni 2004 von $ 14,8 Millionen herunter für dieselbe Periode im Jahr 2003 beendeten Monate. 2004 Kosten reflektieren, dass Forschungs- und Entwicklungskosten steigerten, die der Gesellschaft in erster Linie zuschreibbar sind, "s hilft Impfstoff und rheumatischem Arthritisprogrammen und höherem General und Verwaltungskosten, wenn es Zunahmen von Patenterteilungen und regulierenden Einhaltungskosten reflektiert. 2003 Kosten beinhalteten, Gebühren von $ 2,9 Millionen für die drei Monate und $ 3,2 Millionen für die sechs Juni beendeten Monate umzustukturieren, als 30, 2003, sich mit $ ,2 Millionen und $ vergleichen ließ, ,4 Millionen für die Gleichen Perioden in 2004.

Zweites Viertel beinhalten Höhepunkte: - erfolgreiche Übergangsanalyse von der Gesellschaft "s Mukoviszidose durchführen IIb klinische Probe schrittweise; Probe auf Spur für Fertigstellung bis Jahresende; - richtete Genetik "AAV Technik hob in 12 Darstellungen beim 7. jährlichen Treffen von der amerikanischen Gesellschaft der Gentherapie hervor; - Darstellung von positiven preclinical Daten von der Gesellschaft "s rheumatisches Arthritisprogramm bei ASGT, das vollständige Unterdrückung der Krankheit während Studiums nach intramuskulärer Spritze demonstriert; - Erteilung des zusätzlichen Patents, das gerichteter Genetik exklusive Rechte auf AAV1 gibt, ausgedehntes Potential für zukünftige Produktentwicklung liefert und sich Gelegenheiten zusammenschließt; - Ankündigung der Fusionsvereinbarung zwischen CellExSys und Chromos molekularen Systemen; und - Erteilung einer exklusiven weltweiten Lizenzvereinbarung mit den nationalen Instituten der Gesundheit (NIHs) für Patente, die ITR bedecken (letzte Wiederholung umkehrten), sortiert als Förderer zum Gebrauch mit AAV in jedem Produkthinweis.

Gerichtete Genetik entwickelt genbasierte Produkte für das Verhindern und das Behandeln von bekommenen und erhaltenen Krankheiten. Die Gesellschaft hat drei klinische Produktentwicklungsprogramme, wenn sie Mukoviszidose, AIDS-Prophylaxe und rheumatische Arthritis richtet. Die Gesellschaft hat auch eine viel versprechende Rohrleitung von auf Bluterkrankheit und Krebs gerichteten Produktkandidaten und eine breite Bühne von Genliefertechniken. Zwecks weiterer Informationen über die Gesellschaft besuchen ihre Website bei http://www.targetedgenetics.com/.

Hinweis: Diese Freigabe enthält vorausblickende Erklärungen bezüglich unseren geplanten finanziellen Ressourcen, geistigem Eigentum, klinischen Prüfungen und regulierenden Spänen und erwarteten Fakten von unseren Klinischen und preclinical Programmen. Diese Erklärungen, einschließen gegenwärtige Erwartungen, Vorhersagen von zukünftigen Ereignissen und andere Erklärungen, die nicht historische Fakten sind. Unrichtig, dass Annahmen und bekannte und unbekannte Risiken und Ungewissheiten die Genauigkeit von vorausblickenden Erklärungen beeinflussen kann. Tatsächliche Ergebnisse konnten sich materiell von Erwartungen aus einer Anzahl von Gründen unterscheiden und Unterlassen unserer Partner, Finanzierung zu liefern, unser Unterlassen unser Unterlassen einschließen, zu Fortschritt bei unseren klinischen Prüfungen zu machen, positive Ergebnisse von unseren preclinical Programmen zu erhalten, unser Ausfall zu gelten oder zu behaupten regulierend Einverständnisse, unser Ausfall zu behaupten oder zu schützen unser Intellektueller Eigenschaft und das Anderer riskiert beschrieb in das Abschnitt berechtigte "zerlegt beeinflussen unser laufen resultiert, Unser Geschäft und unser Vorrat zeichnen aus "in unserem vierteljährlichen Bericht über Form 10-Q für das Viertel endete 31. März 2004. Sie sollten nicht übermäßig von diesen vorausblickenden Erklärungen abhängen, die zutreffen, nur wie vom Datum dieser Freigabe. Wir übernehmen keine Pflicht, öffentlich von Revisionen zu diesen Erklärungen anzukündigen oder zu berichten, dass, wie neue Information verfügbar wird, das unsere Erwartung ändern kann.

Gerichtete Genetikgesellschaft (in Tausenden, außer pro Anteil Information), die (nicht testierte) drei Monate sechs Monate 30. Juni, 30. Juni als 2004 2003 2004 2003 Erklärung der Operationsinformation beendet beendeten: Kooperative Vereinbarungen mit Mitgliedern $ 2.761 $ 2.053 $ 4.081 $ 7.692 Verwaltungskosten: Forschung & Entwicklung allgemeines 4.828 4.327 9.065 8.869 & Verwaltungs2.066 1.438 3.816 2.774 stukturieren um berechnet 221 2.899 416 3.180 totalen Verwaltungskosten 7.115 8.664 13.297 14.823 Verlust von Operations- (4.354) (6.611) (9.216) (7.131) Investitionseinkommen 21 56 145 108 Zinskosten (117) (360) (237) (722) Nettoverlust$ 4.450$ (6.915) $ (9.308) $ (7.745) verdient Verlust netto pro bei Berechnung des Nettoverlusts pro Stammaktie 81.604 51.694 77.239 51 verwendete Stammaktien$ (0,05) $ (0,13) $ (0,12) $ (0,15) Aktien,133 richtete Genetikgesellschaft (in Tausenden) 30. Juni, 31. Dezember 2004 2003 (nicht testierte) Bilanzinformation: Einzulösen und einzulösen Äquivalente $ 37.381 $ 21.057 andere Umlaufvermögen 554 575 Eigenschaft und Ausrüstung, Netto2.876 3.423 andere Vermögenswerte 32.462 32.617 Gesamtvermögen $ 73.273 $ 57.672 gegenwärtige Verbindlichkeiten $ 8.328 $ 6.709 langfristige Verpflichtungen und andere Verbindlichkeiten, die 16.231 16.734 Vorzugsaktien und Minderheit interessieren - 750 Aktionäre "Eigenkapital 48.714 33.479 totale Verbindlichkeiten und Aktionäre" Eigenkapital$ 73,273$ 57.672

Gerichtete Genetikcorporation

[bl21]

Heute über 11Prozent inden usa,gibt es News oder reiner zufall?

[BarnyXXL]

Irgendwas im Busch, schaut mal ins Yahoo-Board !

[BarnyXXL]

Gestern + 16 %

[bl21]

Gibt es irgend welche News?

[BarnyXXL]

Möglicherweise das hier, weiß aber nichts genaues.

Und: 200-Tage-Linie gestern durchbrochen !

http://www.medadnews.com/News/Index.cfm?articleid=195907

[bl21]

Ich träume immer noch von den anvisierten 54 dollar kursziel,es wäre einfach zu schön um wahr zu sein.Die sollen endlich ihr Krebs-medikament auf den Markt bringen und uns 2005 alle reichen machen.

[BarnyXXL]

Da träume ich auch schon lange von,

aber ob es schon 2005 sein wird ?

[BarnyXXL]

Sehr schlechte Nachrichten :

17.03.2005 15:14
Targeted Genetics Announces Preliminary Results From Its Phase II Trial of tgAAVCF in Cystic Fibrosis

SEATTLE, March 17 /PRNewswire-FirstCall/ -- Targeted Genetics (Nachrichten) today reported that its Phase II clinical trial of tgAAVCF in patients with mild to moderate cystic fibrosis (CF) failed to meet its primary endpoint of statistically significant improvement in lung function, 30 days following initial administration of tgAAVCF compared to placebo. Based on these results, the Company has decided not to pursue further development of tgAAVCF. The Company will hold a conference call via webcast at 10:30 a.m. EST today, which can be accessed, along with replay information, at http://www.targetedgenetics.com/

`Although we are obviously disappointed that these results did not confirm findings from our earlier Phase II trial in cystic fibrosis, we have significantly expanded our adeno-associated virus (AAV)-related development capabilities and infrastructure through the evaluation of this product candidate,` said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. `We are dedicated to developing products with both clinical and commercial potential and our experience in CF and understanding of AAV from this program will be leveraged into our other development programs. We plan to focus our efforts on our clinical programs in HIV/AIDS prophylaxis, inflammatory arthritis, and our preclinical programs in hyperlipidemia, congestive heart failure and Huntington`s disease.`

Parker further stated, `I would like to take this opportunity to thank the Cystic Fibrosis Foundation, the members of the CF medical community and, especially, CF patients and their families for their support of our efforts to develop a new approach to treating this disease.`

This Phase II, double-blind, randomized, placebo-controlled study was partially funded by Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, and was being conducted through CFFT`s Therapeutics Development Network. The primary end-point of this trial was an improvement in FEV1 lung function 30-days following initial administration of tgAAVCF. The study also evaluated improvement in lung function at day 90, which was 60 days following the administration of a second dose of tgAAVCF, and monitored the safety and tolerability profile of tgAAVCF. A total of 102 patients, 12 years of age and older, were evaluated, 51 in the treatment group and 51 in the placebo group. Study participants received two doses of 1x1013 DNAse resistant particles (DRP) of tgAAVCF or placebo, delivered via nebulizer at day 0 and day 30 of the study and were evaluated for change in FEV1 lung function every two weeks over the course of 90 days. The Company expects to present the complete data set from the study in a peer reviewed forum later this year. The company will continue to collect safety data through the end of the study.

About Targeted Genetics

Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has clinical product development programs, targeting AIDS prophylaxis and inflammatory arthritis. The Company also has a promising pipeline of product candidates focused on hyperlipidemia, congestive heart failure and Huntington`s disease that are being developed under collaboration agreements with others, and a broad platform of gene delivery technologies for application in nucleic acid-based drug development. For more information about Targeted Genetics, visit its website at http://www.targetedgenetics.com/. Contact: Stacie D. Byars 206-521-7392

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our research programs, clinical trials, our revised product development and clinical trial focus and our potential to leverage our development platforms and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company`s new strategic direction and its potential effects on the Company`s business are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, delay or failure in developing our other product candidates, the timing, nature and results of our research and our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property related to any of our product candidates, and our ability to raise capital when needed, as well as other risk factors described in the section entitled `Factors Affecting Our Operating Results, Our Business and Our Stock Price` in our Annual Report on Form 10-K for the year ended December 31, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Contact: Stacie D. Byars, Director, Communications of Targeted Genetics Corporation, [phone].

[bl21]

50 Dollar kursziel,ich lach mich gleich Tot!

[Boersenkrieger]

geile abzocke... da wurden mal wieder viele lemminge gebraten und gebrutzelt

[BarnyXXL]

FinanzNachrichten.de, 22.08.2005 22:32:00
Targeted Genetics Announces Todd E. Simpson to Step Down as Chief Financial Officer

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation announced today that Todd E. Simpson, its Vice President, Finance and Administration, Chief Financial Officer, Treasurer and Secretary will leave October 3, 2005 to accept a position with another company.

David Poston, Targeted Genetics` Senior Director of Finance and Assistant Corporate Secretary, will serve as acting Chief Financial Officer for the company upon Mr. Simpson`s departure. David joined the company in January 1999 and currently leads its finance and accounting operations including internal and SEC financial reporting and financial controls, internal controls, budgeting, treasury and all financial aspects of corporate collaborations. David has over twenty years of financial experience, has had primary responsibility for public company financial disclosure matters since 1993 and started his career in public accounting at KPMG in 1985.

"While we wish Todd well in his endeavors, we are pleased that David will be assuming the role of Acting CFO. David`s extensive experience and tenure at the company managing our financial resources make him a natural choice as Acting CFO to facilitate a smooth transition," said H. Stewart Parker, President and Chief Executive Officer.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington`s disease, and hyperlipidemia. To learn more about Targeted Genetics, visit our website at http://www.targetedgenetics.com/.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our business strategy, our product development, our personnel and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company`s future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation [phone]

[abauer1050]

IAVI Begins First Phase II Preventive HIV Vaccine Trial in South Africa to Test Targeted Genetics` HIV Vaccine Candidate

SEATTLE & NEW YORK--(BUSINESS WIRE)--Nov. 14, 2005--Targeted Genetics Corporation (NASDAQ:TGEN) and The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase II trial in South Africa to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine candidate that is based on HIV subtype C, the subtype of the virus most prevalent in southern and eastern Africa.

This is the first Phase II HIV vaccine trial to be held in South Africa. Candidate vaccines that are proven to be safe in Phase I trials move on to Phase II trials, allowing investigators to test the immune response and acquire more data on safety.

The trial will be conducted in three sites in South Africa: Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital in Soweto with Dr. Eftyhia Vardas as the principal investigator; Desmond Tutu Institute for HIV Research, University of Cape Town, with Dr. Linda-Gail Bekker as the principal investigator; and Medunsa Campus of the University of Limpopo with Professor Anwar Hoosen as the principal investigator. IAVI also plans to test the vaccine in Zambia and Uganda, pending regulatory approval in those countries.

"We are pleased that South Africa has taken a leading role in the testing of vaccine candidates given the medical and humanitarian promise a preventive vaccine holds," said Dr. Eftyhia Vardas of the Perinatal HIV Research Unit, who is the national protocol chair of the trial.

South Africa approved its first HIV vaccine trials in 2003, including one sponsored by IAVI. In 1999, the government created the South African AIDS Vaccine Initiative (SAAVI) to coordinate the research, development, and the testing of HIV vaccines. SAAVI is the national coordinating body for vaccine research in South Africa, working with both national and international partners.

"Developing an AIDS vaccine for the regions of the world in greatest need will take many more innovative partnerships like this one given the difficult scientific challenges we face," said Seth Berkley, M.D., CEO and President of IAVI. "Preventive vaccines have ended or helped control the most deadly infectious diseases known to man. Finding a vaccine to stop the spread of the HIV virus must be a global priority."

"Southern Africa has been devastated by AIDS, and we believe that evaluating tgAAC09 in this region could potentially advance development of this promising vaccine candidate while supporting the global effort to halt the HIV pandemic," said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. "Targeted Genetics and our partners are implementing a multi-faceted clinical trials program for tgAAC09 that is designed to generate robust data in a rapid and rigorous manner. We are pleased to be working with IAVI and SAAVI in the fight against HIV/AIDS."

About the Vaccine Candidate

The vaccine candidate, tgAAC09, utilizes a recombinant adeno-associated viral vector (rAAV) that was developed with and manufactured by Targeted Genetics Corporation, based in Seattle, Washington, USA. Under the terms of a public-private collaboration, IAVI is funding development, pre-clinical, and clinical studies to test the vaccine. The Phase II trial follows positive safety data received from the Phase I trial conducted over the past two years in Belgium, Germany, and India where volunteers received a lower-dose range.

Targeted Genetics` AAV development process is based on a cell line which was designed by Philip R. Johnson, MD., at the Children`s Research Institute on the campus of Children`s Hospital, in Columbus, Ohio, USA. Dr. Johnson is now Chief Scientific Officer at the Children`s Hospital of Philadelphia, Pennsylvania, USA.

About the Trial

The trial should take about 18 months to complete and will enroll 78 volunteers in total -- men and women -- who are in good health. tgAAC09 is designed to elicit two different types of immune responses, an antibody response and a cell mediated response. The vaccine consists of an artificially made copy of the HIV virus and cannot cause HIV infection or AIDS.

IAVI estimates that there are 30 preventive HIV vaccine candidates in human trials on six continents.

About IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization working to accelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996 and operational in 23 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI also advocates for a vaccine to be a global priority and works to assure that a future vaccine will be accessible to all who need it. IAVI`s financial and in-kind supporters include the Bill & Melinda Gates Foundation, the Rockefeller Foundation, Alfred P. Sloan and Starr Foundations; the Governments of Canada, Denmark, the European Union, Ireland, the Netherlands, Norway, Sweden, the United Kingdom, the United States and the Basque Country; multilateral organizations such as the World Bank; corporate donors including BD (Becton, Dickinson & Co.), Continental Airlines and DHL; leading AIDS charities such as Crusaid, Deutsche AIDS Stiftung, and the Until There`s A Cure Foundation; and other private donors such as the Phoebe W. Haas Charitable Trust B. For more information, see www.iavi.org.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington`s disease and hyperlipidemia. To learn more about Targeted Genetics, visit our website at: www.targetedgenetics.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements regarding our regulatory filings, research programs, clinical trials, product development and potential related to tgAAC09. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to recruit and enroll suitable trial participants, the timing, nature and results of our research and our clinical trials, our ability to raise capital when needed, our ability to obtain and maintain regulatory or institutional approvals, and, our ability to protect our intellectual property, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.

CONTACT: Targeted Genetics, Seattle
Stacie D. Byars, 206-521-7392
[e-mail]
or
IAVI, Johannesburg
Gracelle Gerber, + 27 11 504 4001/ [phone]
[e-mail]
or
IAVI, New York
Ellena Friedman, 212-847-1090/646-755-1973
[e-mail]

SOURCE: Targeted Genetics Corporation